June's AI-picked stock updates now live. See what's new in Tech Titans, up 28.5% year to date.Unlock Stocks

Cowen analyst says Amazon should buy Rite Aid

Published 11/21/2017, 11:13 AM
© Reuters.  Cowen analyst says Amazon should buy Rite Aid
AMZN
-
US90274J5618=UBSS
-
  • A Cowen analyst says Amazon (NASDAQ:AMZN) should acquire Rite Aid (NYSE:RAD) for faster access to the legal side of the pharmacy business.
  • Analyst John Blackledge says the Rite Aid buy would bring along pharmacy licenses and infrastructure that could benefit the company if moving to open pharmacies in Whole Foods or to offer medication through the Prime services.
  • Blackledge says the firm’s research shows that 67% of Amazon Prime members would buy prescription drugs through the platform.
  • Blackledge estimates Amazon’s U.S. retail pharmacy business could generate $20B in 2019 with the Rite Aid deal.
  • Amazon shares are up 1.02%.
  • Rite Aid shares are up 3.53%.
  • Now read: 2017 Santa Rally: The Inevitable Change In Retail Stories


Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.